 Stephanie Nakano
Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiomyopathy, Dilated | 5 | 2019 | 352 | 1.590 |
Why?
| | Heart Transplantation | 6 | 2022 | 671 | 1.380 |
Why?
| | Heart Ventricles | 6 | 2020 | 713 | 1.260 |
Why?
| | Phosphodiesterase 3 Inhibitors | 3 | 2019 | 13 | 1.190 |
Why?
| | Myocardium | 3 | 2017 | 929 | 1.160 |
Why?
| | Phosphoric Diester Hydrolases | 3 | 2016 | 44 | 1.160 |
Why?
| | Cardiomyopathy, Hypertrophic | 6 | 2023 | 121 | 1.070 |
Why?
| | Heart Failure | 7 | 2023 | 1963 | 1.070 |
Why?
| | Milrinone | 2 | 2021 | 25 | 0.720 |
Why?
| | Graft Rejection | 1 | 2022 | 533 | 0.660 |
Why?
| | Troponin I | 1 | 2019 | 68 | 0.660 |
Why?
| | Myocytes, Cardiac | 3 | 2019 | 457 | 0.660 |
Why?
| | Heart Defects, Congenital | 3 | 2021 | 660 | 0.590 |
Why?
| | Adenylyl Cyclases | 1 | 2016 | 84 | 0.540 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2016 | 82 | 0.530 |
Why?
| | Down-Regulation | 2 | 2017 | 605 | 0.520 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2018 | 504 | 0.510 |
Why?
| | Calcium | 1 | 2019 | 1103 | 0.450 |
Why?
| | Genetic Therapy | 1 | 2014 | 267 | 0.420 |
Why?
| | Death, Sudden, Cardiac | 4 | 2023 | 160 | 0.410 |
Why?
| | Child, Preschool | 10 | 2023 | 9164 | 0.410 |
Why?
| | Coronary Artery Disease | 1 | 2018 | 613 | 0.400 |
Why?
| | Child | 15 | 2023 | 18537 | 0.370 |
Why?
| | RNA | 1 | 2016 | 820 | 0.360 |
Why?
| | Defibrillators, Implantable | 2 | 2023 | 286 | 0.300 |
Why?
| | Biomarkers | 1 | 2018 | 3474 | 0.300 |
Why?
| | Myocardial Contraction | 3 | 2019 | 316 | 0.300 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2365 | 0.290 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2017 | 319 | 0.260 |
Why?
| | Cystic Fibrosis | 1 | 2014 | 960 | 0.240 |
Why?
| | Humans | 23 | 2023 | 115859 | 0.230 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2023 | 103 | 0.220 |
Why?
| | Electrocardiography | 2 | 2023 | 560 | 0.210 |
Why?
| | Pseudohypoparathyroidism | 1 | 2022 | 3 | 0.210 |
Why?
| | Infant | 4 | 2023 | 7992 | 0.200 |
Why?
| | Male | 13 | 2023 | 56103 | 0.200 |
Why?
| | Arrhythmias, Cardiac | 2 | 2022 | 279 | 0.180 |
Why?
| | Adenosine Monophosphate | 2 | 2021 | 49 | 0.180 |
Why?
| | Blalock-Taussig Procedure | 1 | 2020 | 3 | 0.180 |
Why?
| | Heart Bypass, Right | 1 | 2020 | 15 | 0.180 |
Why?
| | Clinical Decision-Making | 1 | 2022 | 273 | 0.170 |
Why?
| | Exercise Test | 1 | 2022 | 541 | 0.170 |
Why?
| | Patient-Specific Modeling | 1 | 2020 | 37 | 0.170 |
Why?
| | Ventricular Septum | 1 | 2019 | 9 | 0.170 |
Why?
| | Resource Allocation | 1 | 2019 | 38 | 0.170 |
Why?
| | General Practice | 1 | 2019 | 27 | 0.170 |
Why?
| | Biopsy | 1 | 2022 | 1056 | 0.160 |
Why?
| | Female | 12 | 2023 | 60070 | 0.160 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2018 | 22 | 0.160 |
Why?
| | Cardiomyopathies | 1 | 2022 | 303 | 0.160 |
Why?
| | Adolescent | 8 | 2023 | 17935 | 0.160 |
Why?
| | Educational Status | 1 | 2020 | 413 | 0.150 |
Why?
| | Phosphorylation | 2 | 2019 | 1562 | 0.150 |
Why?
| | Calcium-Binding Proteins | 2 | 2016 | 206 | 0.150 |
Why?
| | Risk | 1 | 2019 | 829 | 0.140 |
Why?
| | Risk Factors | 5 | 2023 | 8715 | 0.140 |
Why?
| | Genetic Markers | 1 | 2017 | 336 | 0.140 |
Why?
| | Ventricular Remodeling | 1 | 2018 | 225 | 0.140 |
Why?
| | Ventricular Function, Right | 1 | 2018 | 252 | 0.140 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2017 | 113 | 0.140 |
Why?
| | Models, Statistical | 1 | 2020 | 612 | 0.140 |
Why?
| | Carrier Proteins | 1 | 2019 | 703 | 0.130 |
Why?
| | Fibrosis | 1 | 2017 | 458 | 0.130 |
Why?
| | Public Health | 1 | 2019 | 438 | 0.130 |
Why?
| | Cells, Cultured | 2 | 2019 | 3914 | 0.120 |
Why?
| | Heart-Assist Devices | 1 | 2019 | 486 | 0.110 |
Why?
| | Age Factors | 2 | 2020 | 2911 | 0.110 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2012 | 43 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 796 | 0.100 |
Why?
| | Blotting, Western | 1 | 2014 | 1153 | 0.100 |
Why?
| | Pediatrics | 1 | 2019 | 985 | 0.100 |
Why?
| | Infant, Newborn | 2 | 2023 | 5084 | 0.100 |
Why?
| | Cohort Studies | 4 | 2023 | 4960 | 0.100 |
Why?
| | Retrospective Studies | 4 | 2023 | 12615 | 0.090 |
Why?
| | Young Adult | 4 | 2023 | 10508 | 0.090 |
Why?
| | Genomics | 1 | 2014 | 653 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 2014 | 685 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2020 | 2164 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2019 | 9163 | 0.080 |
Why?
| | Adaptation, Physiological | 1 | 2012 | 477 | 0.080 |
Why?
| | Risk Assessment | 3 | 2023 | 2992 | 0.070 |
Why?
| | Obesity | 1 | 2019 | 2523 | 0.070 |
Why?
| | Prognosis | 1 | 2014 | 3344 | 0.070 |
Why?
| | Echocardiography | 2 | 2019 | 565 | 0.070 |
Why?
| | Cyclic AMP | 2 | 2019 | 227 | 0.060 |
Why?
| | Middle Aged | 2 | 2016 | 27078 | 0.060 |
Why?
| | United States | 1 | 2019 | 12319 | 0.060 |
Why?
| | Chromogranins | 1 | 2022 | 12 | 0.050 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 1 | 2022 | 8 | 0.050 |
Why?
| | Cardiac Output, Low | 1 | 2021 | 64 | 0.050 |
Why?
| | Cardiotonic Agents | 1 | 2021 | 119 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2020 | 61 | 0.040 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2019 | 10 | 0.040 |
Why?
| | Pharmacogenomic Testing | 1 | 2019 | 54 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2018 | 3054 | 0.040 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2018 | 36 | 0.040 |
Why?
| | Internationality | 1 | 2019 | 147 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 816 | 0.030 |
Why?
| | Prevalence | 1 | 2022 | 2270 | 0.030 |
Why?
| | Aged | 1 | 2014 | 19292 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2018 | 780 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1088 | 0.030 |
Why?
| | Polymorphism, Genetic | 1 | 2019 | 633 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 478 | 0.030 |
Why?
| | Up-Regulation | 1 | 2018 | 824 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2018 | 2262 | 0.030 |
Why?
| | Adult | 1 | 2014 | 30814 | 0.030 |
Why?
| | Algorithms | 1 | 2020 | 1494 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2020 | 2807 | 0.030 |
Why?
| | Connexin 43 | 1 | 2012 | 23 | 0.030 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2012 | 99 | 0.030 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2012 | 171 | 0.020 |
Why?
| | Body Mass Index | 1 | 2019 | 1974 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2590 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 4443 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 6276 | 0.020 |
Why?
| | Signal Transduction | 1 | 2019 | 4527 | 0.020 |
Why?
| | Animals | 1 | 2018 | 32158 | 0.010 |
Why?
|
|
Nakano's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|